Corneal neovascularization during experimental fungal keratitis

Molecular Vision

Volumn 15, Issue , 2009, Pages 1988-1996

  Yuan, Xiaoyong ^a   Wilhelmus, Kirk R ^a  

^a CULLEN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; FEMALE; KERATOMYCOSIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANTIBODIES; CANDIDA ALBICANS; CANDIDIASIS; CORNEA; CORNEAL NEOVASCULARIZATION; EYE INFECTIONS, FUNGAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; KERATITIS; KINETICS; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349684717     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12:242-9.
2. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing. Trans Am Ophthalmol Soc 2006; 104:264-302.
3. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27:331-71.
4. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293:1509-13.
5. Chévez-Barrios P. Are we getting closer to prevention and treatment of corneal neovascularization? Clin Experiment Ophthalmol 2007; 35:689-90.
6. Schreiber W, Olbrisch A, Vorwerk CK, Konig W, Behrens-Baumann W. Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis. Invest Ophthalmol Vis Sci 2003; 44:2634-43.
7. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49:522-7.
8. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281:951-61.
9. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48:2545-52.
10. Wu TG, Wilhelmus KR, Mitchell BM. Experimental keratomycosis in a mouse model. Invest Ophthalmol Vis Sci 2003; 44:210-6.
11. Cursiefen C, Wenkel H, Martus P, Langenbucher A, Seitz B, Kuchle M. Standardisiertes Beurteilungsschema zur semiquantitativen Analyse der kornealen Neovaskularisation mittels projizierter Hornhautfotografien. Pilotstudie nach Nicht-Hochrisiko-Keratoplastik vor anschliessender Immunreaktion. Klin Monatsbl Augenheilkd 2001; 218:484-91.
12. Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 2008; 87:462-70.
13. Yuan X, Mitchell BM, Wilhelmus KR. Gene profiling and signaling pathways of Candida albicans keratitis. Mol Vis 2008; 14:1792-8.
14. Yuan X, Mitchell BM, Wilhelmus KR. Expression of matrix metalloproteinases during experimental Candida albicans keratitis. Invest Ophthalmol Vis Sci 2009; 50:737-42.
15. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37:1625-32.
16. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39:18-22.
17. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113:1040-50.
18. Edelman JL, Castro MR, Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci 1999; 40:1112-23.
19. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001; 75:9828-35.
20. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41:2514-22.
21. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000; 70:419-28.
22. Cursiefen C, Rummelt C, Küchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor α, and transforming growth factor β1 in human corneas with neovascularization. Cornea 2000; 19:526-33.
23. Xue ML, Thakur A, Willcox M. Macrophage inflammatory protein-2 and vascular endothelial growth factor regulate corneal neovascularization induced by infection with Pseudomonas aeruginosa in mice. Immunol Cell Biol 2002; 80:323-7.
24. Nanbu PN, Wakabayashi T, Yamashita R, Hayashi H, Hisano S, Oshika T. Heat treatment enhances healing process of experimental Pseudomonas corneal ulcer. Ophthalmic Res 2004; 36:218-25.
25. -/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2007; 48:4498-508.
26. Ashman RB, Papadimitriou JM. Endothelial cell proliferation associated with lesions of murine systemic candidiasis. Infect Immun 1994; 62:5151-3.
27. Barker KS, Park H, Phan QT, Xu L, Homayouni R, Rogers PD, Filler SG. Transcriptome profile of the vascular endothelial cell response to Candida albicans. J Infect Dis 2008; 198:193-202.
28. Biswas PS, Banerjee K, Kinchington PR, Rouse BT. Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp Eye Res 2006; 82:46-54.
29. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-9.
30. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-42.
31. Lee S, Zheng M, Kim B, Rouse BT. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest 2002; 110:1105-11.
32. Pakneshan P, Birsner AE, Adini I, Becker CM, D'Amato RJ. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci 2008; 49:3909-13.
33. O'Day DM, Ray WA, Head WS, Robinson RD, Williams TE. Influence of corticosteroid on experimentally induced keratomycosis. Arch Ophthalmol 1991; 109:1601-4.
34. Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007; 79:389-94.
35. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007; 35:745-8.
36. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008; 145:424-31.
37. Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008; 27:349-52.
38. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C. Structure-function studies of two synthetic antivascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006; 281:6625-31.